PDF(Pubmed)
Abstract：
UNASSIGNED: Macular edema (ME) is a vision-threatening condition that commonly develops as a consequence of ocular diseases, including age-related macular degeneration, retinal vaso-occlusion of the central retinal vein and its branches, diabetic retinopathy, central serous chorioretinopathy, uveitis, retinitis pigmentosa, pseudophakia, ocular trauma, and drug toxicity. The treatment of ME remains challenging, although steroids and vascular endothelial growth factor inhibitors are available. Cost-effective therapy using a noninvasive administration route is required. This study aimed at reviewing the role of carbonic anhydrase inhibitors (CAIs) in the management of ME.
UNASSIGNED: A literature search was conducted using PubMed/MEDLINE and Google Scholar for studies from January 2000 to March 2022. The following keywords were used in various combinations: \"macular edema\", \"carbonic anhydrase\", \"carbonic anhydrase inhibitors\", \"acetazolamide\", \"dorzolamide\", and \"brinzolamide\".
UNASSIGNED: Articles with high or medium clinical relevance were selected for this review. We found that multiple studies have demonstrated the relevance and efficacy rates of CAIs in the management of ME. Most published studies focused on acetazolamide and dorzolamide, with nearly all studies reporting therapeutic responses.
UNASSIGNED: ME is the leading cause of vision loss and requires noninvasive and cost-effective pharmacotherapy. With progress in the understanding of ME, particularly the role of carbonic anhydrase as a key driver, CAIs are the focus of research. Further optimization of the choice of CAIs and retinal bioavailability, potentially with nanoparticle formulations, is required to enable the effective management of ME. Further research is warranted to address the therapeutic effects of CAIs in different formulations.
UNASSIGNED: A literature search was conducted using PubMed/MEDLINE and Google Scholar for studies from January 2000 to March 2022. The following keywords were used in various combinations: \"macular edema\", \"carbonic anhydrase\", \"carbonic anhydrase inhibitors\", \"acetazolamide\", \"dorzolamide\", and \"brinzolamide\".
UNASSIGNED: Articles with high or medium clinical relevance were selected for this review. We found that multiple studies have demonstrated the relevance and efficacy rates of CAIs in the management of ME. Most published studies focused on acetazolamide and dorzolamide, with nearly all studies reporting therapeutic responses.
UNASSIGNED: ME is the leading cause of vision loss and requires noninvasive and cost-effective pharmacotherapy. With progress in the understanding of ME, particularly the role of carbonic anhydrase as a key driver, CAIs are the focus of research. Further optimization of the choice of CAIs and retinal bioavailability, potentially with nanoparticle formulations, is required to enable the effective management of ME. Further research is warranted to address the therapeutic effects of CAIs in different formulations.
摘要：
■黄斑水肿（ME）是一种威胁视力的疾病，通常是眼部疾病的结果，包括年龄相关性黄斑变性,视网膜中央静脉及其分支的视网膜血管阻塞，糖尿病视网膜病变，中心性浆液性脉络膜视网膜病变,葡萄膜炎,视网膜色素变性,假晶状体,眼外伤,和药物毒性。ME的治疗仍然具有挑战性，虽然类固醇和血管内皮生长因子抑制剂是可用的。需要使用非侵入性给药途径的具有成本效益的治疗。本研究旨在回顾碳酸酐酶抑制剂（CAIs）在ME管理中的作用。
■从2000年1月至2022年3月，使用PubMed/MEDLINE和GoogleScholar进行了文献检索。以下关键字以各种组合使用：“黄斑水肿”，“碳酸酐酶”，“碳酸酐酶抑制剂”，“乙酰唑胺”，“多佐胺”，和“布林佐胺”。
■选择具有高或中等临床相关性的文章进行本综述。我们发现，多项研究已经证明了CAI在ME管理中的相关性和有效性。大多数已发表的研究集中在乙酰唑胺和多佐胺，几乎所有的研究报告治疗反应。
■ME是视力丧失的主要原因，需要非侵入性和具有成本效益的药物治疗。随着对ME的理解的进步，特别是碳酸酐酶作为关键驱动因素的作用，CAI是研究的重点。进一步优化CAIs的选择和视网膜生物利用度，潜在的纳米颗粒配方，是有效管理ME所必需的。需要进一步的研究来解决CAI在不同制剂中的治疗效果。
■从2000年1月至2022年3月，使用PubMed/MEDLINE和GoogleScholar进行了文献检索。以下关键字以各种组合使用：“黄斑水肿”，“碳酸酐酶”，“碳酸酐酶抑制剂”，“乙酰唑胺”，“多佐胺”，和“布林佐胺”。
■选择具有高或中等临床相关性的文章进行本综述。我们发现，多项研究已经证明了CAI在ME管理中的相关性和有效性。大多数已发表的研究集中在乙酰唑胺和多佐胺，几乎所有的研究报告治疗反应。
■ME是视力丧失的主要原因，需要非侵入性和具有成本效益的药物治疗。随着对ME的理解的进步，特别是碳酸酐酶作为关键驱动因素的作用，CAI是研究的重点。进一步优化CAIs的选择和视网膜生物利用度，潜在的纳米颗粒配方，是有效管理ME所必需的。需要进一步的研究来解决CAI在不同制剂中的治疗效果。
